Serological markers of Hepatitis B virus, 26 years after first immunization in Cuba

Authors

  • Maria Caridad Montalvo Villalba Instituto de Medicina Tropical Pedro Kouri https://orcid.org/0000-0001-7496-023X
  • Licel de los Ángeles Rodríguez Lay Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.
  • Dayesi Lopez Hernández Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.
  • Marite Bello Corredor Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.
  • Manuel Díaz González Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.
  • Idamis Fernández Jure Banco de Sangre Provincial de Villa Clara, Santa Clara, Cuba.
  • Yaima Esther González Suno Centro Provincial de Higiene y Epidemiología de Santiago de Cuba, Cuba.
  • Hilda Cabrales Rondón Banco de Sangre Provincial de Santiago de Cuba
  • Ariel Legrá Ayala Banco Provincial de Sangre de La Habana.

Keywords:

hepatitis B virus, Heberbiovac HB, single nucleotide polymorphism, interleukin 12

Abstract

Introduction: Prevention and control of hepatitis B in Cuba has been possible due to introduction of Cuban vaccine Heberbiovac HB, in the National Program of Immunization (NPI). Actually, our health system has the challenge to achieve the elimination of hepatitis B. Objective. To evaluate the prevalence of infection (HBsAg, DNA HBV) and protection (antibodies anti-HBsAg) markers of hepatitis B virus, in blood donors and a vulnerable group, and identify the influence of the immunogenetics of the Cuban population in humoral response to Heberbiovac HB vaccine. Methods: Hepatitis B virus markers for infection and protection were measured in blood donors and patients under hemodialysis treatment, using immunoenzymatic and molecular assays. Also, nucleotide sequencing was used to determine single nucleotide polymorphisms (SNP) of interleukin 12 (IL-12), IL-12A G>A e IL-12B A>C, in individuals boosted with a single dose of Heberbiovac HB. Results: HBsAg prevalence was low in Cuban blood donors, and zero in donors born after the implementation of HBV vaccination in NPI. In hemodialysis patients, HBsAg prevalence was 5,95%, and 89,47% of them had protector levels of anti-HBsAg. In individuals with SNP IL-12 combinations IL-12A/IL-12B; GG/AC and GG/AA hiperprotectors levels of anti-HBsAg were identified, post-vaccination, as opposed to the AA/AA combination. Conclusions. The findings show the immunogenicity of Heberbiovac HB and confirm the efficacy of the Cuban vaccination program. It was demonstrated for the first time that IL-12 SNP could impact the level of anti-HBsAg antibodies after immunization in the Cuban population.

Downloads

Download data is not yet available.

Author Biographies

Maria Caridad Montalvo Villalba, Instituto de Medicina Tropical Pedro Kouri

Investigador Titular, Laboratorio Nacional de Referencia de Hepatitis Virales, Dpto. Virologia, Centro de Diagnóstico, Investigaciones y Referencia, IPK.

Licel de los Ángeles Rodríguez Lay, Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.

Investigador y Profesor Titular, Departamento de Virología, Centro de Diagnóstico Investigación y Referencia.

Dayesi Lopez Hernández, Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.

Aspirante a Investigador, Departamento de Virología, Centro de Diagnóstico Investigación y Referencia.

Marite Bello Corredor, Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.

Investigador y Profesor Auxiliar, Departamento de Virología, Centro de Diagnóstico Investigación y Referencia.

Manuel Díaz González, Instituto de Medicina Tropical Pedro Kourí, Habana, Cuba.

Profesor Titular, Departamento de VirologEpidemiología, Centro de Diagnóstico Investigación y Referencia.

Idamis Fernández Jure, Banco de Sangre Provincial de Villa Clara, Santa Clara, Cuba.

Dra. en Medicina, Responsable del Banco de Sangre Provincial de Villa Clara, Santa Clara

Yaima Esther González Suno, Centro Provincial de Higiene y Epidemiología de Santiago de Cuba, Cuba.

Licenciada en Enfermeria, Responsable del Programa de Hepatitis Virales, Departamento de Microbiología.

Hilda Cabrales Rondón, Banco de Sangre Provincial de Santiago de Cuba

Especialista en Medicina General Integral, Directora del Banco Provincial de Santiago de Cuba. 

Ariel Legrá Ayala, Banco Provincial de Sangre de La Habana.

Licenciado en Bioanálisis clínico, Banco Provincial de Sangre de La Habana.

Downloads

Published

2021-04-26

How to Cite

Montalvo Villalba, M. C., Rodríguez Lay, L. de los Ángeles, Lopez Hernández, D., Bello Corredor, M., Díaz González, M., Fernández Jure, I., … Legrá Ayala, A. (2021). Serological markers of Hepatitis B virus, 26 years after first immunization in Cuba. Anales De La Academia De Ciencias De Cuba, 11(2), e836. Retrieved from https://revistaccuba.sld.cu/index.php/revacc/article/view/836

Issue

Vol. 11 No. 2 (2021): mayo-agosto

Section

Biomedical sciences

License

The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.

The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.

Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.

To learn more, see https://creativecommons.org